Last reviewed · How we verify
Bevacizumab Injection
Bevacizumab Injection is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved. Also known as: Avastin, Pobevcy, Bevacizumab, dexamethasone implant injection.
At a glance
| Generic name | Bevacizumab Injection |
|---|---|
| Also known as | Avastin, Pobevcy, Bevacizumab, dexamethasone implant injection, Concurrent low-dose Bevacizumab |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab Injection CI brief — competitive landscape report
- Bevacizumab Injection updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Bevacizumab Injection
What is Bevacizumab Injection?
Bevacizumab Injection is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Bevacizumab Injection?
Bevacizumab Injection is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
Is Bevacizumab Injection also known as anything else?
Bevacizumab Injection is also known as Avastin, Pobevcy, Bevacizumab, dexamethasone implant injection, Concurrent low-dose Bevacizumab.
What development phase is Bevacizumab Injection in?
Bevacizumab Injection is FDA-approved (marketed).
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Also known as: Avastin, Pobevcy, Bevacizumab, dexamethasone implant injection, Concurrent low-dose Bevacizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing